Intranasal flunisolide is an effective treatment for allergic rhinitis. Flunisolide has high bioavailability when administered to normal subjects (50% of an intranasal dose reaches the .systemic circulation) with minimal systemic effects. Bioavailability in patients with active rhinitis averages 62.4 ± 15.7%. The oral dose bioequivalent to 100 [ig intranasally is 500 Hg. To define the comparative trial and systemic effects of intranasal flunisolide in patients with active allergic rhinitis, a multicenter, randomized, double-blind, placebo-controlled study was conducted during the 1983 ragweed hayfever season. Ninety-nine patients with ragweed hayfever for &2 years and positive prick skin tests to ragweed were randomly allocated to one of three treatment groups: 0 = oral flunisolide 500 ng b.i. Patients were evaluated by a blinded observer every 2 weeks and were globally evaluated at the study's end. Data were analyzed for each center and pooled. There were no significant differences in symptom severity of sneezing, nasal congestion, and throat itch in the 0 (oral flunisolide) and P (placebo) groups. N (nasal flunisolide) was significantly more effective than 0 or P (P « 0.005) for each symptom for at least one 2-week period. Global evaluation demonstrated control of overall hayfever severity for N (nasal flunisolide) but not for 0 (oral flunisolide). We conclude that the therapeutic efficacy of flunisolide is achieved by topical and not by systemic action.
Intranasally administered corticosteroids are the oral drug. In the aforementioned dosages, now recognized as effective agents in the thera-however, dexamethasone was associated with py of allergic rhinitis (3, 4, 5, 7, 10, 11) yet litde adrenal suppression (1) by both routes, data is available concerning the relative contriSince this study was completed there have bution of topical versus systemic drug effects in been no further published reports addressing the relief of symptomatology.
the question of systemic versus topical efficacy. In 1966, Norman et al. (6) compared tbe With the advent of newer synthetic corticoeffects of 1 mg dexametbasone applied to the steroids such as flunisolide, which are substannasal mucosa with the oral dosage which pro-tially inactivated by first pass hepatic metavided the equivalent systemic effects (0.3 mg) as bolism and not associated with adrenal supmeasured by adrenal suppression. The data pression in the recommended maximal dosages indicated that the topical route was superior to (up to 200 (ig/day) (2, 3, 7), the question of systemic versus topical efficacy has attracted renewed interest.
In one human study (8) it was demonstrated that tbe effects of topical administration of 200 fig flunisolide on total circulating eosinophils were not different from those of placebo or 1 mg oral prednisone. However, the oral administration of 2.5 mg prednisone or more resulted in a significant fall in the total eosinophil count.
More recently, in a human study involving 14 patients (9), the areas under the curve of plasma fiunisolide after a 100 |xg topical dose were quite similar and bioequivalent to a 500 | Xg dose administered orally.
To define the comparative clinical effects of locally applied with orally administered flunisolide in dosages providing similar plasma profiles, a comparative treatment study was conducted during the 1983 ragweed pollen season.
MATERIAL AND METHODS
Ninety-nine adult patients with clearly defined seasonal symptoms of allergic rhinitis and positive immediate whealing skin test reactions to ragweed pollen were entered into the study at four centers in cities of the upper Mid-west: Madison, Wisconsin, Rochester, Minnesota; Ann Arbor, Michigan; and Iowa City, Iowa. In each center, all patients were entered just prior to the local ragweed pollen season. Each patient, after being screened for suitability and providing informed consent, kept a daily record of the duration of nasal, pbaryngeal and conjunctival symptoms and tbe use of chlorpheniramine (4 mg) for 1 week. At the end of the week each patient rated tbe severity of symptoms when present. Each then was assigned randomly to treatment with either a) flunisolide nasal spray plus oral placebo, b) oral flunisolide plus placebo nasal spray, or c) oral and nasal spray placebo. Patients were randomly assigned to treatments using a restricted randomization with a block size of six. For each consecutive group of six patients enrolled by an investigator, two patients were assigned to either the nasal, oral, or placebo treatment group. This insured that the sample size for the three groups would be approximately equal. Flunisolide nasal spray consisted of the currently available 0.025 % solution delivered by a hand-activated pump spray unit furnishing 25 [xg of drug per activation. Oral fiunisolide was provided in opaque capsules containing 500 fig of drug. Placebos consisted of nasal spray vehicle or capsules containing an inert powder. Patients were instructed to use two sprays in each nostril and swallow one capsule twice a day. These doses provided a total of 200 [xg and 1000 [xg, respectively, of flunisolide per day in the two treatment arms. Chlorpheniramine maleate (4 mg) was furnished to be used on an as needed basis.
Thereafter, each subject continued to record the duration of symptoms and extent of chlorpheniramine use on a daily basis for 4 weeks. Each participant had a clinical evaluation at the end of 2 and again at 4 weeks of treatment. At the end of the 4-week study period each subject was asked to rate the degree of symptomatic benefit achieved by comparison with severity recalled in prior years. Daily pollen counts were recorded at each participant's center. In addition, tbe University of Iowa group independently made smears of the nasal secretions for eosinophils at each visit.
The human research committee in each center approved the conduct of the study prior to its initiation. All materials were supplied by Syntex, Inc., Palo Alto, CA. None of the patients was receiving immunotherapy or corticosteroids.
Tests performed on the study data included the nonparametric Kruskal-Wallis test for overall treatment differences, Duncan's multiple range test for pairwise treatment comparisons, and repeated measures analysis of variance (ANOVA) for overall treatment differences and treatment by time and treatment by investigator interactions. Treatment differences were considered statistically significant at the two-tailed P ^ 0.05 level of significance.
RESULTS AND DISCUSSION
Analysis of the data obtained revealed no clinically meaningful differences in either demo-graphics or in prior season symptom severity among the three treatment groups arms and the four treatment centers (Table 1) .
All patients entered the study just prior to high pollen counts and began a baseline period of symptom scoring and prn ingestion of chlorpheniramine. Then tbe double-blind study began and continued through the pollen season. Representative pollen levels obtained in Ann Arbor are displayed in Fig. 1 .
Of the 99 patients entered, all but two completed the treatment phase. The two not completing did so for non-study related reasons. During the baseline observation week the patients in the three treatment groups had similar symptoms and used similar amounts of antihistamine. After the double-blind study began, the three groups had significantly different degrees of morbidity. The group treated with topically applied flunisolide had significandy shorter duration of nasal stuffiness and sneezing per day, fewer days when these symptoms lasted 2 b or more per day and less severity when these symptoms were present than did those treated with oral fiunisolide or placebo. No significant differences were noted for these parameters between the latter two groups. In addition, those patients treated with fiunisolide nasal spray used significantly fewer doses of cblorpheniramine during the treatment month than did the other two groups. By contrast, the nonnasal symptom "eye itch" was never significantly different among the three treatment periods. This supports the hypothesis that the therapeutic effects of intranasal flunisolide are largely local (Figs. 2-4) .
In accord with these responses, tbe treatment evaluations recorded at the end of the doubleblind study month and the comparison with prior season experience also significantly favored the flunisolide nasal spray treatment, with no differences noted between the oral fiunisolide and placebo treatment groups (Table 2) .
It can also be seen in Fig. 5 that the patients receiving topical fiunisolide had a decline in eosinophils in their nasal secretions during the season in contrast to those treated with placebo. A lesser decline is present in the orally treated group. However, the numbers of patients in each group are too few for meaningful statistical analysis.
Adverse effects were noted by 63% of the patients in the study. The most common was transient nasal burning and stinging immediately on application of the nasal spray. It was experienced by 47% of the fiunisolide intra- nasal group, 33% of the oral fiunisolide group and 41 % of the placebo group.
Five patients experienced mild epistaxis (one nasal fiunisolide, three oral fiunisolide and two placebo) and five experienced medication-related sneezing (two nasal fiunisolide, one oral fiunisolide and two placebo). None was severe enough to require stopping tbe medication or to require treatment. nasal spray is due to its local action and not to systemic absorption. This is further confirmed by tbe pattern of changes in the number of eosinopbils in the nasal secretions during the season.
